Bernstein raises Centene stock price target to $68 on Medicaid outlook

Bernstein SocGen Group raised Centene’s price target to $68 from $48 while keeping an Outperform rating, implying about 24% upside from the current $54.60 share price. The firm sees Medicaid operating performance stabilizing and 2027 earnings drivers improving, though it trimmed 2026 Marketplace margin guidance to 3% from 4% due to worse-than-expected risk pool shifts. Centene also reported strong Q1 2026 results, with adjusted EPS of $3.37 versus $2.13 expected and revenue of $49.94 billion versus $47.58 billion consensus.

Analysis

The clean read-through is that the market is still underappreciating the asymmetry between 2026 and 2027 for managed care. Near-term, the stock is being repriced on credibility of earnings power rather than just headline growth: if Medicaid cost trend is truly converging toward rate, then the earnings floor rises materially and the multiple can expand before any full margin recovery shows up. That matters because investors typically wait for actual margin inflection; here, the setup is to buy the re-rating one to two quarters ahead of consensus.

The second-order winner is not just CNC itself but the broader Medicaid-heavy managed care complex, because the key signal is that cost pressure may be peaking earlier than feared. If Centene can demonstrate stabilization while peers still debate acuity normalization, it creates a template for contract renewals and rate negotiations across the sector. The likely loser is any operator still exposed to the same state programs but without Centene’s scale or contracting leverage; they will look more vulnerable if states anchor rate discussions off these improving trends.

The main risk is that the market is baking in a 2027 recovery story before the marketplace risk pool fully resets. That gap can persist for months, and if risk adjustment or state rate actions disappoint, the stock can de-rate quickly because the current valuation is more dependent on forward confidence than on trailing numbers. The catalyst path is therefore not linear: the next two quarterly updates matter more than the full-year guide, because they will determine whether this is a genuine multi-year inflection or just a temporary stabilization.

Consensus may be missing that the better trade is not necessarily a straight long on 2026 improvements, but a long-duration optionality on 2027 earnings power versus a near-term hedge. If the market keeps paying for visible downside protection in Medicaid but underestimates the pace of margin normalization, the spread between CNC and weaker peers should widen before absolute upside is exhausted. The risk/reward is attractive as long as investors avoid overpaying after the recent run and size for a guide-reset scenario in Marketplace.

Key Decisions for Investors

• Maintain/add to CNC on any post-earnings pullback; target a 3-6 month horizon where the market re-rates 2026 earnings credibility before 2027 margin recovery is fully visible. Risk/reward remains favorable if downside is capped by stabilizing Medicaid economics, but trim if the stock trades above the implied value of the new target range without further guide upside.
• Pair trade: long CNC / short a weaker Medicaid-exposed managed care name with less scale and thinner margin buffers over the next 1-2 quarters. The thesis is that rate-cost normalization will separate the best operators from the rest before broad sector multiples expand.
• Buy CNC call spreads 6-9 months out to express the 2027 optionality without paying full delta after the recent move. This is attractive if you believe the next two prints validate the recovery story but want protection against a Marketplace guide reset.
• If you already own CNC, hedge with a short-term put spread into the next earnings or regulatory update window. The stock is now more sensitive to any evidence that risk pools or risk adjustment are not keeping pace, and the hedge limits gap risk on a disappointment.
• Watch for confirmation in peers' commentary on Medicaid cost trend and state rate discussions; if those improve, add to the basket, but if peers diverge negatively, reduce CNC and keep only the higher-conviction 2027 optionality.